DE60019122D1 - Veränderter faktor viii - Google Patents

Veränderter faktor viii

Info

Publication number
DE60019122D1
DE60019122D1 DE60019122T DE60019122T DE60019122D1 DE 60019122 D1 DE60019122 D1 DE 60019122D1 DE 60019122 T DE60019122 T DE 60019122T DE 60019122 T DE60019122 T DE 60019122T DE 60019122 D1 DE60019122 D1 DE 60019122D1
Authority
DE
Germany
Prior art keywords
factor viii
amino acid
changed factor
changed
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019122T
Other languages
English (en)
Other versions
DE60019122T2 (de
Inventor
S Lollar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Application granted granted Critical
Publication of DE60019122D1 publication Critical patent/DE60019122D1/de
Publication of DE60019122T2 publication Critical patent/DE60019122T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
DE60019122T 1999-05-20 2000-05-16 Veränderter faktor viii Expired - Lifetime DE60019122T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US315179 1999-05-20
US09/315,179 US6376463B1 (en) 1992-04-07 1999-05-20 Modified factor VIII
PCT/US2000/013541 WO2000071141A1 (en) 1999-05-20 2000-05-16 Modified factor viii

Publications (2)

Publication Number Publication Date
DE60019122D1 true DE60019122D1 (de) 2005-05-04
DE60019122T2 DE60019122T2 (de) 2006-02-09

Family

ID=23223252

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019122T Expired - Lifetime DE60019122T2 (de) 1999-05-20 2000-05-16 Veränderter faktor viii

Country Status (12)

Country Link
US (2) US6376463B1 (de)
EP (1) EP1200105B1 (de)
JP (1) JP3964622B2 (de)
AT (1) ATE291923T1 (de)
AU (1) AU765442B2 (de)
CA (1) CA2374675C (de)
CY (1) CY1110360T1 (de)
DE (1) DE60019122T2 (de)
ES (1) ES2238284T3 (de)
HK (1) HK1043543A1 (de)
PT (1) PT1200105E (de)
WO (1) WO2000071141A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2002248329B2 (en) * 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002337901B2 (en) * 2001-10-05 2008-01-17 Expression Therapeutics Llc Nucleic acid and amino acid sequences encoding high-level expressor factor VIII polypeptides and methods of use
WO2003047507A2 (en) * 2001-11-30 2003-06-12 Emory University Factor viii c2 domain variants
CN102139114A (zh) * 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
BRPI0410289A (pt) * 2003-05-07 2006-05-16 Pfizer Prod Inc ligantes do receptor de canabinóides e suas utilizações
EP1636360A4 (de) * 2003-06-03 2006-11-08 Cell Genesys Inc Zusammensetzungen und verfahren zur verstärkten expression rekombinanter polypeptide von einem vektor unter verwendung einer peptidspaltstelle
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
CA2547569C (en) * 2003-12-03 2013-04-16 University Of Rochester Recombinant factor viii having increased specific activity
SI1750733T1 (sl) 2004-05-03 2014-03-31 Emory University POSTOPEK DAJANJA PRAĹ IÄŚJEGA fVIII BREZ DOMENE B
PL1824988T3 (pl) * 2004-11-12 2018-01-31 Bayer Healthcare Llc Ukierunkowana na miejsce modyfikacja czynnika VIII
US20100256062A1 (en) * 2004-12-06 2010-10-07 Howard Tommy E Allelic Variants of Human Factor VIII
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP2711436A1 (de) 2007-11-01 2014-03-26 University Of Rochester Rekombinanter Faktor VIII mit erhöhter Stabilität
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
CA2780761A1 (en) * 2009-11-13 2011-05-19 Puget Sound Blood Center Factor viii t cell epitope variants having reduced immunogenicity
CA2782424C (en) 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP2524054A2 (de) * 2010-01-14 2012-11-21 Haplomics, Inc. Vorhersage und reduktion der alloimmunogenität von proteintherapeutika
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
ES2721478T3 (es) * 2010-11-05 2019-07-31 Baxalta Inc Nueva variante del factor VIII antihemofílico que tiene actividad específica aumentada
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
ES2722209T3 (es) 2011-07-08 2019-08-08 Bioverativ Therapeutics Inc Polipéptidos quiméricos e híbridos del Factor VIII, y métodos de uso de los mismos
WO2013016454A1 (en) 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
TR201816253T4 (tr) 2012-01-12 2018-11-21 Bioverativ Therapeutics Inc Faktör VIII terapisi almakta olan bireylerde faktör VIII'e karşı immünojenisiteyi azaltmanın yöntemleri.
CA2863328A1 (en) 2012-01-12 2013-07-18 Biogen Idec Ma Inc. Chimeric factor viii polypeptides and uses thereof
SI3564260T1 (sl) 2012-02-15 2023-02-28 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njegove izdelave in uporabe
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
EA029685B1 (ru) 2012-07-11 2018-04-30 Амуникс Оперэйтинг Инк. Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (de) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
TWI629993B (zh) 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
EP3904376A1 (de) 2013-06-24 2021-11-03 Xiao, Weidong Mutante faktor-viii-zusammensetzungen und verfahren
EA201592022A1 (ru) 2013-06-28 2016-05-31 Байоджен Ма Инк. Расщепляемый тромбином линкер, содержащий xten, и его применение
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
EP3033097B1 (de) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Faktor viii-xten fusionen sowie ihre verwendungen.
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
ES2967617T3 (es) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Herramientas de farmacocinética poblacional y sus usos
CN114736305B (zh) 2014-01-10 2023-05-05 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
EP3114138B1 (de) 2014-03-05 2021-11-17 Pfizer Inc. Verbesserte muteine von gerinnungsfaktor viii
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
JP2021523878A (ja) 2018-05-18 2021-09-09 バイオベラティブ セラピューティクス インコーポレイテッド 血友病ａを処置する方法
CN117157316A (zh) 2021-03-30 2023-12-01 艾诺健基因治疗股份有限公司 修饰的血浆凝血因子viii及其使用方法
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US6180371B1 (en) * 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
WO1995018829A1 (en) 1994-01-07 1995-07-13 Novo Nordisk A/S Factor viii derivatives
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität

Also Published As

Publication number Publication date
ES2238284T3 (es) 2005-09-01
AU765442B2 (en) 2003-09-18
DE60019122T2 (de) 2006-02-09
CA2374675A1 (en) 2000-11-30
US6376463B1 (en) 2002-04-23
AU5023700A (en) 2000-12-12
US20030166536A1 (en) 2003-09-04
JP2003508019A (ja) 2003-03-04
US7033791B2 (en) 2006-04-25
HK1043543A1 (en) 2002-09-20
ATE291923T1 (de) 2005-04-15
JP3964622B2 (ja) 2007-08-22
CA2374675C (en) 2012-04-03
CY1110360T1 (el) 2012-05-23
EP1200105B1 (de) 2005-03-30
EP1200105A4 (de) 2003-04-16
EP1200105A1 (de) 2002-05-02
PT1200105E (pt) 2005-06-30
WO2000071141A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
DE60019122D1 (de) Veränderter faktor viii
DK1280540T3 (da) Modificeret faktor VIII
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
DE60004974D1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
ATE279386T1 (de) Retinoide zur behandlung von emphysem
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis
ATE241640T1 (de) Fusidinsäure-derivate
DE69911502D1 (de) Verfahren zur Behandlung von Kunststoffen auf mechanochemischem Weg
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ATE226443T1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis
ATE259809T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition